Related Experiment Videos
Neurological toxicity of ifosfamide
1Department of Neurology, Second Clinic, University of Padova, Padova, Italy.
Oncology
|October 31, 2003
Summary
Ifosfamide, an effective chemotherapy drug, can cause central nervous system toxicity, including metabolic encephalopathy, in 5-30% of patients. This neurotoxicity is usually reversible after stopping the medication.
Area of Science:
- Oncology
- Pharmacology
- Neuroscience
Background:
- Ifosfamide is a widely used alkylating agent for treating various cancers.
- It shares toxicities with cyclophosphamide, such as myelosuppression and urotoxicity.
- Ifosfamide is also associated with distinct adverse neurological effects.
Purpose of the Study:
- To review the characteristics of ifosfamide-induced central nervous system (CNS) toxicity.
- To discuss the incidence, clinical presentation, and potential mechanisms of this neurotoxicity.
- To highlight available therapeutic options for managing ifosfamide-related CNS effects.
Main Methods:
- Literature review of studies on ifosfamide and its neurotoxicity.
- Analysis of reported cases and clinical data regarding CNS adverse events.
- Synthesis of information on the proposed mechanisms and management strategies.
Main Results:
- Ifosfamide-induced CNS toxicity manifests as metabolic encephalopathy, with symptoms varying in severity.
- Reported incidence ranges from 5% to 30% of patients, often linked to high doses or oral administration.
- Neurotoxicity is typically reversible within 48-72 hours after drug discontinuation, though severe outcomes have occurred.
Conclusions:
- Ifosfamide-related neurotoxicity is a significant concern in cancer therapy.
- Understanding the risk factors and clinical presentation is crucial for patient management.
- Effective therapeutic strategies are available to mitigate and treat these neurological adverse effects.